Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
NCT00652054Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tegafur, sponsored by Taiho Oncology. Primary endpoint: Overall Tumor Response Rate at 6 months. Started Jun 2005; status: completed.
02
Drugs
tegafur
Beyond the preview
Go deeper on NCT00652054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652054.